CCAAT/enhancer binding protein beta deficiency provides cerebral protection following excitotoxic injury

J Cell Sci. 2008 Apr 15;121(Pt 8):1224-34. doi: 10.1242/jcs.025031.

Abstract

The CCAAT/enhancer-binding protein beta (C/EBPbeta, also known as CEBPB) was first identified as a regulator of differentiation and inflammatory processes in adipose tissue and liver. Although C/EBPbeta was initially implicated in synaptic plasticity, its function in the brain remains largely unknown. We have previously shown that C/EBPbeta regulates the expression of genes involved in inflammatory processes and brain injury. Here, we have demonstrated that the expression of C/EBPbeta is notably increased in the hippocampus in a murine model of excitotoxicity. Mice lacking C/EBPbeta showed a reduced inflammatory response after kainic acid injection, and exhibited a dramatic reduction in pyramidal cell loss in the CA1 and CA3 subfields of the hippocampus. These data reveal an essential function for C/EBPbeta in the pathways leading to excitotoxicity-mediated damage and suggest that inhibitors of this transcription factor should be evaluated as possible neuroprotective therapeutic agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Injuries / chemically induced
  • Brain Injuries / prevention & control*
  • CCAAT-Enhancer-Binding Protein-beta / genetics*
  • Cells, Cultured
  • Hippocampus / drug effects
  • Immunohistochemistry
  • Kainic Acid / toxicity*
  • Male
  • Mice
  • Rats

Substances

  • CCAAT-Enhancer-Binding Protein-beta
  • Kainic Acid